Analysts Set Insulet Co. (NASDAQ:PODD) Target Price at $272.81

Insulet Co. (NASDAQ:PODD) has been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $272.81.

PODD has been the topic of a number of research analyst reports. Wells Fargo & Company lifted their price target on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Morgan Stanley lifted their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Finally, Citigroup lifted their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.47% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the last quarter. Venturi Wealth Management LLC grew its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. Friedenthal Financial bought a new stake in shares of Insulet during the 4th quarter valued at about $57,000. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares during the last quarter.

Insulet Stock Up 1.1 %

PODD stock opened at $275.81 on Monday. The stock has a market capitalization of $19.35 billion, a P/E ratio of 47.23, a PEG ratio of 3.41 and a beta of 1.22. The company has a 50 day moving average price of $266.30 and a two-hundred day moving average price of $232.46. Insulet has a one year low of $160.19 and a one year high of $279.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.